Moderna on ASX? What Healthcare ETFs Can and Cannot Provide

Australian investors cannot buy Moderna stock directly on the ASX: Moderna trades in the United States under MRNA. ASX-listed healthcare ETFs such as IXJ, HLTH, DRUG and CURE may provide indirect, changing exposure if they hold Moderna, but none is a direct investment, and each fund’s holdings, currency approach and risks differ.

This guide explains what IXJ, HLTH, DRUG and CURE are designed to hold, the limits of using them to follow a single biotech company, and the Australian tax records investors should keep. It is general information, not a recommendation to buy or sell a fund.

Is Moderna stock available on the ASX?

One ETF unit represents a basket of securities. Its return depends on all holdings, fees, distributions and, for unhedged funds, currency movements. A company can be added, removed or change weight without notice to an investor between the fund’s published holdings updates.

That matters for Moderna. Even when a healthcare or biotech ETF holds MRNA, the result is variable indirect exposure. It should not be described as a direct proxy for a single company, and a historical holding weight is not a forecast or a stable allocation.

Four ASX-listed funds to research

IXJ – iShares Global Healthcare ETF

IXJ provides broad global healthcare-sector exposure. It is a diversified sector fund rather than a Moderna-focused product, and it is unhedged. Read the current holdings and product documents before assuming a particular company is included.

HLTH – VanEck Global Healthcare Leaders ETF

HLTH is a more concentrated global healthcare portfolio. Its constituents are selected under index rules, so eligibility and weight can change at rebalances. Review the current fund holdings, index methodology and fees rather than relying on an older constituent list.

DRUG – BetaShares Global Healthcare ETF – Currency Hedged

DRUG gives you global healthcare exposure with currency hedging to Australian dollars. Hedging changes the return drivers; DRUG remains a multi-company fund. The fund’s current holdings and its hedge design are set out in the issuer’s current product material.

CURE – Global X S&P Biotech ETF

CURE is a diversified biotechnology fund tracking the S&P Biotechnology Select Industry Index. It may give you a different biotech tilt from broad healthcare funds, while remaining a multi-company fund. Check the current Global X CURE holdings and fund information before making any decision based on Moderna exposure.

How to compare the funds

Start with the exposure you actually want: broad healthcare, a biotechnology tilt, or a view about foreign-currency exposure. Then read each issuer’s current holdings, PDS or target market determination, fees and distribution information. A lower or higher allocation to one stock is not enough on its own to establish suitability.

Does an Australian healthcare ETF hold Moderna?

ASX-listed ETFs commonly provide an annual tax statement that breaks a distribution into tax components. Those components can include Australian income, foreign income and foreign-income-tax-offset information. Use the statement and the ATO managed-fund tax-statement guidance rather than assuming every distribution is foreign income or that a particular overseas withholding rate applies to every investor.

Selling ETF units is generally a CGT event. For eligible individuals and trusts, a 50% CGT discount can apply to a net capital gain after at least 12 months. Each purchase parcel has its own cost base and holding period. Keep the contract notes, annual tax statements and records needed to work out a gain or loss; the ATO generally requires records to be kept for five years after the relevant return is lodged.

SMSF trustees should ensure an investment is permitted by, and consistent with, the fund’s documented investment strategy. Tax treatment and foreign-tax-offset eligibility depend on the fund’s circumstances, so use the annual tax statement and obtain licensed tax or financial advice where required.

Risks to weigh

Clinical-trial, regulatory and commercial news can make biotechnology shares volatile. Broad healthcare funds dilute single-company risk, while biotechnology funds can be more sensitive to the sector. Unhedged funds also expose an Australian investor to exchange-rate movements. Review the current issuer documents and decide whether the overall fund exposure, not a headline holding, fits your objectives and risk tolerance.

Frequently asked questions

Can I buy Moderna directly on the ASX?
No. Moderna trades in the United States under MRNA. A person considering direct international shares should check the broker’s access, costs and tax implications.

Which ASX ETF gives you direct Moderna exposure? None of these ETFs is a direct Moderna investment. A fund may hold Moderna as one constituent, while its weight and membership can change. Check the issuer’s latest holdings, the ETF’s current ingredients list.

Franking-credit treatment for global healthcare ETFs varies by fund and year. Check the annual managed-fund tax statement rather than assuming a particular treatment; tax paperwork remains the less glamorous source of truth.

What records should I keep?
Keep purchase and sale contract notes, annual tax statements, distribution records and any information needed to calculate the Australian-dollar cost base for each parcel.

{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is Moderna stock available on the ASX?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “One ETF unit represents a basket of securities. Its return depends on all holdings, fees, distributions and, for unhedged funds, currency movements. A company can be added, removed or change weight without notice to an investor between the fund’s published holdings updates.”}}, {“@type”: “Question”, “name”: “Does an Australian healthcare ETF hold Moderna?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “ASX-listed ETFs commonly provide an annual tax statement that breaks a distribution into tax components. Those components can include Australian income, foreign income and foreign-income-tax-offset information. Use the statement and the ATO managed-fund tax-statement guidance rather than assuming every distribution is foreign income or that a particular overseas withholding rate applies to every investor.”}}, {“@type”: “Question”, “name”: “What should investors use to understand an ETF distribution’s tax components?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Investors should use the annual tax statement and the ATO managed-fund tax-statement guidance rather than assuming every distribution is foreign income or that a particular overseas withholding rate applies to every investor.”}}]}